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MicroRNAs (miRNAs) are short, noncoding RNAs that act as key regulators of diverse
biological processes by mediating translational repression or mRNA degradation of target
genes. Recent studies discovered miRNAs in saliva, and these miRNAs are promising
candidates for use as biomarkers of dental diseases. In this review, the results of miRNA
studies in the dental ﬁeld are presented, and a brief overview of the current progress,
limitations, and perspectives regarding miRNA biomarkers for dental diseases is given.
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MicroRNAs (miRNAs) are a class of small single-stranded
noncoding RNAs that were ﬁrst discovered in C. elegans and
later shown to be evolutionarily conserved across many
animal species, including humans [1–3]. MicroRNAs, which; fax: þ82 2 3010 6967.
.-K. Lee).are approximately 22 nucleotides in length, act as key
regulators of diverse biological processes by mediating trans-
lational repression or mRNA degradation of their target genes
[4,5]. The mode of action of these regulators is through
imperfect complementary binding to the 30 untranslated
region (30 UTR) of target mRNAs [4,6]. Typically, a single
Table 1 – Differential expression of miRNAs in oral cancers (Human model).
miRNA Sample source Disease Expression Reference
miR-211 Tissue OSCC Increased Chang et al. [45]
miR-125a, miR-200a Saliva OSCC Increased Park et al. [20]
miR-21, miR-155, let-7i, miR142-3p, miR-423, miR-106b, miR-20a, miR-16 Tissue HNSCC Increased Hui et al. [46]
miR-125b, miR-375, miR-10a Decreased
miR-24 Plasma OSCC Increased Lin et al. [47]
miR-31 Plasma OSCC Increased Liu et al. [22]
miR-99a, miR-100 Tissue HNSCC Decreased Chen et al. [48]
miR-9 Saliva HNSCC Increased Salazar et al. [49]
miR-134, miR-191 Decreased
miR-21 Whole blood OSCC Increased Ren et al. [50]
miR-155 Tissue OSCC Increased Shi et al. [51]
miR-27b Saliva OSCC Increased Momen-Heravi et al. [38]
* Head and neck squamous cell carcinoma (HNSCC), oral squamous cell carcinoma (OSCC).
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translation of hundreds of genes [5,7]. To date, more than
2500 genes encoding miRNAs have been identiﬁed in the
human genome [8,9].
The biogenesis of miRNAs begins with the production of
mRNA-like polyadenylated primary transcripts (pri-miRNA)
by RNA polymerase II. Subsequent miRNA maturation
requires two RNase III proteins, Drosha and Dicer. These
two proteins may collaborate in the stepwise processing of
miRNAs, and also have key roles in the process of miRNA-
mediated gene regulation. The mature single-stranded miR-
NAs are eventually incorporated into a ribonucleoprotein
complex, the RNA-induced silencing complex (RISC). RISC
acts to downregulate gene expression via mRNA cleavage or
translation repression: the miRNA component acts as a guide
[10–14].Circulating microRNAs
Serum and plasma contain large amounts of stable miRNAs,
and these therefore have potential to serve as biomarkers for
speciﬁc physiological and pathological conditions such as
cancer, transplant rejection, cardiac injury, infection, and
others [3,15–18]. The salivary transcriptome, which contains
more than 3000 RNA species, including miRNAs, was recently
released, and salivary miRNA biomarkers are emerging as
tools for the detection of oral cancer and systemic diseases
[19–23]. The miRNAs in saliva have advantages for biomar-
kers compared with other salivary biomarkers like proteins,
mRNAs, DNAs and bacterial products. Even aside from the
distinctive function of miRNA as post-transcriptional regula-
tor, miRNAs are stably present in saliva and the similarity
between miRNA proﬁles of saliva and other body ﬂuids
provide high availability as biomarkers for various human
diseases [21,24,25].
Saliva sampling is a non-invasive, cheap, easy-to-access
alternative to traditional tissue and blood sampling [26,27].
Saliva is an accurate indicator of bodily conditions, and
salivary biomarkers may serve as early diagnostic tools. Saliva
diagnostics is considered to be a highly promising alternative
to classic environmental epidemiology [28,29]. The ease of
sampling and cost effectiveness of saliva-based tests provideadvantages over traditional techniques for large scale
population-based screening studies and also in situations
where repeated sampling is required, such as for monitoring
and managing disease progression [30]. Lab-on-a-chip (LOC)
technologies are beginning to be used in clinical settings for
point-of-care (POC) diagnostics [31]. Saliva samples have been
used successfully for POC detection of multiple disease enti-
ties, including some that cause dental disease [32,33].MicroRNAs as biomarkers for oral cancers
MicroRNAs are important in tumourigenesis due to their
proximity to chromosomal breakpoints and their dysregulated
expression levels in many malignancies [34–36]. Overexpres-
sion of certain miRNAs might result in the downregulation of
tumour suppressor genes, while underexpression of other
miRNAs might cause oncogene upregulation [37,38]. Conse-
quently, several studies evaluated the potential of miRNAs as
diagnostic and prognostic biomarkers for cancers [20,34,39,40].
Approximately 90% of head and neck cancers are oral
squamous cell carcinomas (OSCC). OSCC is an aggressive and
lethal malignancy that is a major worldwide problem due to
its extremely high prevalence and very poor prognosis [41,42].
The average 5-year survival rate for patients with diagnosed
OSCC is approximately 50% [43,44]. Therefore, an early detec-
tion method is needed for OSCC to improve treatment and
long-term patient survival [20]. A number of studies have
evaluated miRNAs as diagnostic biomarkers for OSCC. Differ-
entially expressed miRNAs discovered by these studies are
listed in Table 1.MicroRNAs as biomarkers for periodontitis
Periodontal disease is characterised by inﬂammation of
tooth-supporting structures. Periodontitis, which is a typical
manifestation of periodontal disease, involves progressive
loss of the alveolar bone around the teeth. If left untreated,
periodontitis can lead to tooth loosening and subsequent
tooth loss [52–55]. Associations between periodontal disease
and other general health problems, such as diabetes, cardi-
ovascular disease, rheumatoid arthritis and adverse
Table 2 – MicroRNA research related to periodontal disease.
Target diseases Sample source Methods Results Reference
Periodontitis Healthy and diseased
gingival tissues
miRNA PCR array 6 miRNAs up-regulated Lee et al. [64]
Periodontitis Healthy and diseased
gingival tissues
miRNA Microarray 91 miRNAs up-regulated, 34 miRNAs
down-regulated
Xie et al. [58]
Periodontitis and obesity Gingival biopsy samples miRNA PCR array 11 miRNAs up-regulated Perri et al. [59]
Periodontitis Healthy and diseased
gingival tissues
miRNA Microarray 4 miRNAs up-regulated, 7 miRNAs
down-regulated
Stoecklin-Wasmer et al.
[61]
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indicating the importance of early detection and treatment
of periodontal disease [56]. The development of diagnostic
tools to detect the presence and activity of periodontal
disease is therefore of high importance.
Periodontal disease severity has traditionally been assessed
using clinical parameters like pocket probing depth, clinical
attachment loss, bleeding on probing, and radiographic deter-
mination of alveolar bone loss. Most of these techniques were
establishedmore than ﬁve decades ago, and lack the capacity to
identify highly susceptible patients at risk for disease progres-
sion [28,57]. Periodontitis is a highly complex disease, which
hampers the development of rapid, accurate, diagnostic and
prognostic tests. Nevertheless, the development of innovative
diagnostic tests for periodontal disease remains a high priority.
A small number of miRNA studies related to periodontal
disease have been performed (Table 2). Xie et al. [58] used
microarray analysis to examine miRNA expression, and tran-
script levels of selected inﬂammatory-related miRNAs were
conﬁrmed by quantitative reverse transcription polymerase
chain reaction (qRT-PCR). The study used gingival tissues from
ten healthy subjects and ten patients with periodontitis. Levels
of some miRNAs were more than ﬁve-fold higher in tissues
from periodontitis patients than in control tissues. In addition,
the possible regulation of Toll-lik receptors (TLRs) in period-
ontal inﬂammation by miRNA pathways was also proposed.
A pilot investigation was conducted to determine whether
miRNA expression was altered by obesity or periodontal dis-
ease, and whether there were any potential interactions
between obesity and periodontitis that could involve miRNA
modulation [59]. In this study, gingival biopsy samples were
obtained from 20 patients, ten of who were non-obese (BMIo30
kg/m2) and ten of who were obese (BMI430 kg/m2). Each group
of ten patients contained ﬁve patients with chronic period-
ontitis and ﬁve periodontally healthy patients. This was the ﬁrst
trial to assess the mechanisms underlying the pathogenesis of
periodontitis and a common chronic condition (obesity), as well
as the interaction between the two diseases [60].
Stoecklin-Wasmer et al. [61] examined the occurrence of
miRNAs in healthy and diseased gingival tissues and vali-
dated the in silico-predicted targets through mRNA proﬁling
using whole-genome microarray analysis of the same speci-
mens. Four miRNAs were signiﬁcantly overexpressed, and
seven signiﬁcantly underexpressed, in gingival tissues com-
pared to controls. Gene Set Enrichment Analysis (GSEA)
identiﬁed 60 enriched miRNA gene sets with target genes
involved in immune/inﬂammatory responses and tissuehomeostasis. This was the ﬁrst study to examine concurrent
mRNA and miRNA expression in the same gingival tissues.
Only a handful of studies investigating miRNAs in gingival
tissues have been reported to date. Studies of miRNAs and their
relationships to periodontal disease will be improved in the near
future by the use of diverse samples, including saliva, and this will
allow the inter-relationships of periodontal disease with other
systemic diseases to be ascertained. In addition, some studies
using animal periodontitismodels and dental stem cells have been
conducted [62,63], and these will help determine the mechanisms
underlying the modulation of speciﬁc candidate miRNAs.Limitations of miRNAs as biomarkers
Although the exploitation of miRNAs as biomarkers for
dental diseases is promising, some constraints should be
considered.
First, differentially expressed candidate miRNAs identiﬁed
through pilot studies need to be validated. Most previous
studies using tissues were performed with samples from
small numbers of individuals without matching for potential
confounding factors known to inﬂuence periodontitis sus-
ceptibility such as age and gender. Further validation studies
using large well-characterised cohorts are required [60].
Second, although recent advances in molecular biology and
high-throughput screening techniques have enabled research-
ers to characterise miRNA patterns in body ﬂuids such as
serum, plasma, and saliva on a large scale, this is limited by
the lack of suitable endogenous controls for normalisation of
salivary miRNAs. Recent research attempted to identify endo-
genous control miRNAs displaying minimal expression varia-
bility between samples [38], but endogenous salivary miRNA
controls are required for future exploitation of miRNA data-
sets. In addition, saliva samples collected from the same
individual can display considerable heterogeneity according
to the collection method used, and standardised methods for
sample collection should therefore be considered.
Third, although biomarker development is paramount, the
development of suitable treatment and prevention methods for
patients testing positive for these biomarkers is also required.
Effective, focused treatments are needed for highly susceptible
patients in order to capitalise on early diagnosis, andwithout such
treatments a clear cost-beneﬁt advantage cannot be realised [28].
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The availability of novel genetic testing technologies such as
RNA sequencing will allow current technical limitations to be
circumvented and will increase test accuracy when extremely
small samples are used. Fundamental research into the
mechanisms underlying control and activity of miRNAs will
facilitate the identiﬁcation of links between various diseases.
In addition, more efﬁcient computational prediction models
and improved bioinformatic pipelines will allow optimal use
of miRNA datasets [65–67].
The combination of new diagnostic tests with saliva
sampling will provide easy, rapid, testing, and will enable
large scale and follow-up studies to be conducted at lower
costs than when using traditional blood or tissue samples.
With the introduction of new and improved techniques, more
individuals susceptible to periodontal disease and with poor
prognosis for other conditions will be detected early, allowing
patient-focused clinical treatments. This ﬁrst step will lay the
groundwork for the future development of personalised
dentistry using genetic information.Acknowledgements
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